Mesoblast fuses Phase II
Tuesday, 28 April, 2009
Melbourne’s Mesoblast has received approval to being a Phase II trial of its allogeneic stem cell product NeoFuse in cervical spine fusion.
The trial, to be held at Melbourne’s Epworth Hospital, will compare NeoFuse with autograft. Twenty-four patients with irreversible, end-stage degenerative disc disease will take part in the randomised, controlled trial.
Mesoblast is also working on lumbar spinal fusion and on repair or regeneration of discs in patients with earlier stage disease.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
